- Home
- EMF vs IPHA Comparison
EMF vs IPHA Comparison
Compare EMF & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMF
- IPHA
- Stock Information
- Founded
- EMF 1987
- IPHA 1999
- Country
- EMF United States
- IPHA France
- Employees
- EMF N/A
- IPHA N/A
- Industry
- EMF Finance/Investors Services
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- EMF Finance
- IPHA Health Care
- Exchange
- EMF Nasdaq
- IPHA Nasdaq
- Market Cap
- EMF 192.8M
- IPHA 148.3M
- IPO Year
- EMF N/A
- IPHA 2019
- Fundamental
- Price
- EMF $11.73
- IPHA $1.82
- Analyst Decision
- EMF
- IPHA Strong Buy
- Analyst Count
- EMF 0
- IPHA 1
- Target Price
- EMF N/A
- IPHA $11.50
- AVG Volume (30 Days)
- EMF 29.3K
- IPHA 785.4K
- Earning Date
- EMF 01-01-0001
- IPHA 09-12-2024
- Dividend Yield
- EMF 6.16%
- IPHA N/A
- EPS Growth
- EMF N/A
- IPHA N/A
- EPS
- EMF N/A
- IPHA N/A
- Revenue
- EMF N/A
- IPHA $36,202,722.00
- Revenue This Year
- EMF N/A
- IPHA N/A
- Revenue Next Year
- EMF N/A
- IPHA $102.87
- P/E Ratio
- EMF N/A
- IPHA N/A
- Revenue Growth
- EMF N/A
- IPHA N/A
- 52 Week Low
- EMF $10.58
- IPHA $1.29
- 52 Week High
- EMF $12.67
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- EMF 30.95
- IPHA 47.15
- Support Level
- EMF $11.83
- IPHA $1.64
- Resistance Level
- EMF $12.29
- IPHA $1.95
- Average True Range (ATR)
- EMF 0.14
- IPHA 0.12
- MACD
- EMF -0.00
- IPHA -0.04
- Stochastic Oscillator
- EMF 2.11
- IPHA 35.57
About EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.